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A2 and Enterovirus 71 During the Enterovirus Outbreak in 
Taiwan, 2008: A Children’s Hospital Experience
Shih-Perng Chena, Yhu-Chering Huanga,b*, Wen-Chen Lia,b, Cheng-Hsun Chiua,b, Chung-Guei Huangb,c, 
Kuo-Chien Tsaob,c, Tzou-Yien Lina,b
aDivision of Infectious Diseases, Department of Pediatrics, Chang Gung Children’s Medical Center, Taoyuan, Taiwan.
bChang Gung University College of Medicine, Taoyuan, Taiwan.
cDepartment of Laboratory Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
BACKGROUND/PURPOSE: Coxsackievirus A2 (Cox A2) was the predominant serotype in the enterovirus 
outbreak in Taiwan, 2008. However, detailed clinical features of Cox A2 infection have not been reported. 
In this study, we compared Cox A2 with enterovirus 71 (EV71) in terms of clinical manifestation and 
epidemiology during the 2008 enterovirus outbreak in Taiwan.
METHODS: A total of 280 hospitalized patients (97 with culture-proven EV71 infection and 183 with culture-
proven Cox A2 infection) in 2008 at the Chang Gung Children’s Medical Center were enrolled in this study. 
Epidemiologic data, clinical manifestations, and outcomes for these patients were collected and compared.
RESULTS: Both Cox A2 and EV71 serotypes peaked in June and declined soon afterwards. Seventy-one per-
cent of the patients were younger than 3 years of age. Both groups had the same male-to-female ratio of 1.6:1. 
Patients with EV71 infection had a significantly longer hospitalization period (4.1 vs. 3.0 days, p < 0.001). 
Fever, fever for more than 3 days with a temperature above 39ºC, lethargy, poor activity, poor appetite and a 
myoclonic jerk were significantly associated with EV71 infection. Fever, or fever with a temperature above 39ºC, 
febrile seizure, elevated white cell counts, and elevated serum C-reactive protein concentrations were signifi-
cantly associated with Cox A2 infection. Most patients with EV71 infection presented with hand-foot-mouth 
disease (78.3%), while most Cox A2-infected patients presented with herpangina (83.6%). Central nervous 
system complications were found in 18.6% of EV71-infected children, but only in 1.1% of Cox A2-infected 
children. All the patients with Cox A2 infection showed total recovery. One patient with EV71 infection died 
from encephalitis with cardiopulmonary failure, and 6.2% of EV71-infected children had neurologic sequelae.
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CONCLUSION: Both Cox A2 and EV71 serotypes accounted for the enterovirus outbreak in Taiwanese 
children in 2008. Compared with those infected by EV71, the children with Cox A2 infection mostly pre-
sented with herpangina, had fewer central nervous system complications, and had better overall outcome.
KEYWORDS: coxsackievirus A2, encephalitis, enterovirus 71, hand-foot-and-mouth disease, herpangina
enterovirus infection in 2008. Of these, 193 (27.0%) were 
Cox A2 infected and 109 (15.3%) were EV71 infected. A total 
of 183 Cox A2-infected patients and 97 EV71-infected 
patients were hospitalized and were included in this study. 
Demographic data such as age, gender, and hospitalization 
time were collected. Clinical findings including fever, peak 
body temperatures, symptoms of cough, rhinorrhea, vom-
iting, diarrhea, myoclonic jerk, febrile and afebrile seizures, 
limb weakness, poor appetite, poor activity, lethargy, head-
ache, and consciousness change were recorded. Clinical 
signs including oral ulcers, skin rashes, and laboratory data 
on admission such as white blood cell (WBC) count, hemo-
globin level, platelet count, peak serum C-reactive protein 
(CRP) concentration, cerebrospinal fluid were routinely 
collected for comparison. Data regarding the final diagno-
sis and outcome were also collected.
Diagnostic definitions
Herpangina was defined as the presence of oral ulcers on 
the anterior tonsillar pillars, and a soft palate, buccal mu-
cosa or uvula. Patients with HFMD had oral ulcers on the 
tongue or the buccal mucosa, and vesicular rashes over 
the palms, soles, knees, or buttocks. Fever was defined as 
body temperature ≥ 38ºC. Leukocytosis was defined as 
WBC count ≥ 17.5 × 103/μL. For the complicated cases, 
meningitis was defined as pleocytosis on cerebrospinal 
fluid analysis. Encephalitis was characterized by the 
presence of altered levels of consciousness, personality 
changes, or hallucinations. Encephalomyelitis included 
both encephalitis and myelitis-like syndrome, which had 
the characteristics of acute paralysis, or acute limb weak-
ness with decreased muscle power. Pulmonary hemor-
rhage was defined as alveolar congestion on a chest X-ray 
and fresh blood from the endotracheal tube.12
Viral isolation and serotyping
Throat and rectal swabs were collected from 714 patients for 
viral isolation and serotyping using monoclonal antibodies 
Introduction
In the past, enteroviruses were classified into polioviruses, 
echoviruses, coxsackievirus A and B, and later, the enterovi-
ruses were denoted by numbers, such as enterovirus 68 to 
71.1 In 2000, King et al classified enteroviruses by genomic 
sequencing as human enteroviruses A to D (4 species).2 
Since its first isolation in California in 1969, enterovirus 
71 (EV71) outbreaks have been reported worldwide.3,4 It 
can cause a wide spectrum of diseases, ranging from fe-
brile illness, hand-foot-and-mouth disease (HFMD), her-
pangina, meningitis to encephalitis, and even death.5–9
In Taiwan, a large-scale epidemic of EV71 in 1998 caused 
78 deaths.4 From 2000 to 2001, an epidemic took place 
and 20–30 deaths were reported. Small-scale outbreaks 
were seen from 2002 to 2005, and thereafter it seemed to 
decline for the following 2 years. The epidemic re-surfaced 
in late 2007 in Southern Taiwan and spread to Northern 
Taiwan by early 2008.10,11 As predicted, a large-scale EV71 
outbreak commenced in April 2008.
By June of 2008, an alarming increase in the numbers 
of coxsackievirus A2 (Cox A2) isolates was reported by our 
virology laboratory, as well as other contracted virology 
laboratories of Center for Disease Control and Prevention, 
Taiwan. Among the enteroviral isolates, EV71 and Cox A2 
were the two most common serotypes. Since the detailed 
clinical features of Cox A2 infection had not been reported 
before, these findings prompted us to study these clinical 
features in patients infected with Cox A2. Here, we de-
scribe the clinical manifestations, epidemiology, and out-
comes of the patients with Cox A2 infection and compare 
the data with those due to EV71 infection.
Methods
Patients
A total of 714 patients in Chang Gung Children’s Hospital, 
Taoyuan, Taiwan were confirmed (by viral culture) to have 
 101
Comparison of clinical features between Cox A2 and EV71
and neutralization tests. Isolates were cultured with human 
fetal lung fibroblast (MRC-5), Rhesus monkey kidney epi-
thelial cells (LLC-MK2), human epidermoid cancer cells 
(Hep-2), and human rhabdomyosarcoma (RD) cells. When 
enteroviral cytopathic effects affected more than 50% of the 
cell monolayer, indirect fluorescent antibody staining 
with panenteroviral antibody (Chemicon International, 
Temecula, CA, USA) was performed to identify the enterovi-
rus. One-hundred and nine patients were identified as 
EV71-positive by immunofluorescence using an anti-EV71 
monoclonal antibody (Chemicon International). Taiwanese 
Center for Disease Control and Prevention provided a cox-
sackie A virus blend for further subtyping of those patients 
that tested positive for Cox A. Eventually, 193 patients were 
identified as having Cox A2 infections.12
Statistical analysis
Data were analyzed using the SPSS version 13.0 (SPSS Inc., 
Chicago, IL, USA). Student’s t test was used for continu-
ous variables and the χ2 test was used for categorical data. 
A p < 0.05 was regarded as statistically significant.
Results
Monthly distribution
Between January and March 2008, no Cox A2-infected case 
was reported. One case of Cox A2 infection was identified in 
April. The number of Cox A2-infected cases dramatically in-
creased by June, with 118 cases identified. Afterwards, Cox 
A2 isolates declined sharply and no further cases were ob-
served by the end of December. As for EV71, cases were found 
throughout the study period from January to December 
2008. Few cases were reported in the early months. Similar 
to Cox A2, EV71 infection peaked in June, with 28 cases 
identified. However, unlike Cox A2, EV71 saw a steady rate 
of detection throughout from July to December (Figure).
Patient demographics
The demographic data of the patients are shown in Table 1. 
There was no significant difference between the median 
age of patients with EV71 and Cox A2 infection. The ma-
jority of the patients were less than 3 years of age (68.3% in 
the Cox A2 group and 76.3% in the EV71 group). Gender 
distribution did not differ significantly between the two 
groups, both having a male-to-female ratio of 1.6:1. The 
EV71 group had a significantly longer median hospitali-
zation time than the Cox A2 group (p < 0.001).
Clinical manifestation
The clinical manifestations of these patients are summa-
rized in Table 2. Fever for more than 3 days, fever greater than 
39ºC, fever greater than 39ºC combined with fever for more 
than 3 days, lethargy, poor oral intake, poor activity, a myo-
clonic jerk, oral ulcers, and skin rashes were significantly 
more frequent in patients with EV71 infection. In contrast, 
the presence of fever, fever greater than 39ºC, and febrile 
seizures were significantly more frequent in patients with 
Cox A2 infection. The incidence and presence of cough, 
rhinorrhea, vomiting, diarrhea, and headache were similar 
between the two groups. Ataxia, limb weakness and an 
unsteady gait were only seen in those with EV71 infection.
Laboratory data
Compared with those with EV71 infection, patients with 
Cox A2 infection had a significantly higher median WBC 
count and median CRP level. Moreover, leukocytosis and 
CRP > 40 mg/L were significantly more frequent in pa-
tients with Cox A2 infection (Table 2). In terms of hemo-
globin level and platelet count, there were no significant 
differences between the two groups.
Final diagnosis
Table 3 illustrates the final diagnoses of these patients. 
A total of 78.4% of the patients with EV71 infection mani-
fested as HFMD, while 83.6% of the patients with Cox A2 
infection had herpangina. Of the patients with EV71 in-
fection, 18 (18.6%) had central nervous system (CNS) in-
volvement, while only two (1.1%) patients with Cox A2 
infection had CNS involvement.
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Outcome
Ninety patients (92.8%) with EV71 infection showed com-
plete recovery. Six patients (6.5%) had sequelae, including 
limb weakness in two patients, epilepsy in three patients, 
and two-limb disability (one upper limb ad one lower limb) 
due to the complication of post-extracorporeal membrane 
oxygenation, with resultant amputation in one patient. The 
only one fatal case was a 3 year-old male who was admitted 
for fever, vomiting, lethargy and a frequent myoclonic jerk. 
He developed myocarditis and pulmonary hemorrhage soon 
after admission and deteriorated rapidly. Despite the use of 
post-extracorporeal membrane oxygenation, he eventually 
died after 56 days of hospitalization. All patients with Cox A2 
infection had complete recovery without sequelae (Table 3).
Table 1. Comparison of the demographics between the patients with coxsackievirus A2 and enterovirus 71a
Variables EV71 (n = 97) Cox A2 (n = 183) p
Age (yr) 1.9 (0.54–11.54) 2.1 (0.08–14.83) 0.285
Age < 3 yr 74 (76.3) 125 (68.3) 0.250
Sex, M:F 1.6:1 1.6:1 0.903
Length of hospitalization (d) 4.1 (1–63) 3.0 (1–16) < 0.001
aData presented as median (range) or n (%). M = Male; F = female.
Table 2. Comparison of clinical manifestations and laboratory data between the patients with coxsackievirus A2 and enterovirus 71a
Symptoms EV71 (n = 97) Cox A2 (n = 183) p
Fever 92 (94.8) 182 (99.5) 0.005
 ≥ 3 days 62 (63.9) 60 (32.8) < 0.001
 ≥ 39ºC 51 (52.5) 134 (73.2) < 0.001
 ≥ 3 days & 39ºC 39 (40.2) 45 (24.6)  0.017
Cough 21 (21.6) 63 (34.4) 0.031
Rhinorrhea 21 (21.6) 51 (27.9) 0.273
Vomiting 28 (28.8) 69 (37.7) 0.120
Diarrhea 6 (6.1) 18 (9.8) 0.358
Lethargy 23 (23.7) 16 (8.7) 0.001
Poor oral intake 77 (79.3) 119 (65.0) 0.025
Poor activity 59 (60.8) 85 (46.4) 0.037
Myoclonic jerk 48 (49.4) 53 (28.4) 0.001
Febrile seizure 2 (2.0) 16 (8.7) 0.038
Altered consciousness 8 (8.2) 4 (2.2) 0.047
Ataxia 5 (5.1) 0 0.037
Limb weakness 6 (6.1) 0 0.004
Unsteady gait 2 (2.0) 0 0.335
Oral ulcer 93 (95.8) 159 (86.9) 0.023
Skin rash 83 (85.5) 17 (9.3) < 0.001
WBC count (/μL) 12,200 (5.1–24.6) 14,200 (2.9–33.3) 0.001
 WBC =17,500/μL 11 (11.3) 46 (25.1) 0.006
CRP (mg/L) 9.43 (0.4–103.4) 30.00 (0.5–243.0) < 0.001
 CRP > 40 mg/L 9 (9.3) 77 (42.1) < 0.001
aData presented as n (%) or median (range). WBC = White blood cell; CRP = C-reactive protein.
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Discussion
In this study, we found that the clinical features are differ-
ent between these two viral serotypes. Patients with Cox 
A2 infection mostly presented with herpangina, and rarely 
had CNS complications. In contrast, patients with EV71 
infection mostly presented with HFMD, had more CNS 
complications (even resulting in cardiopulmonary failure 
with fatal outcome), and had more neurologic sequelae.
More than 95% of the patients in this study, either 
with Cox A2 or EV71 infection, had fever. Two-thirds of 
the patients with EV71 infection even had fever for more 
than 3 days, which is consistent with our previous find-
ings.12 Lethargy and myoclonic jerk, both indicative of 
CNS involvement, were more frequently seen in patients 
with EV71 infection. Forty-nine percent of patients with 
EV71 infection in this study had a myoclonic jerk, which 
is compatible with our previous observations.13 However, 
it is intriguing that febrile seizures were significantly more 
frequent in patients with Cox A2 infection at a rate of 
8.7%, which is higher than that in the general population 
of this age (∼5%). Since lumbar puncture was not performed 
in most of these cases, we cannot link CNS infection di-
rectly to these patients. Other nonspecific symptoms such 
as cough, rhinorrhea, vomiting, and diarrhea were not sig-
nificantly different between the two groups.
In this study, more than three quarters of EV71-
infected patients manifested as HFMD; most patients 
with CNS complications also initially presented as HFMD. 
These findings are consistent with previous observations 
from Taiwan.12–16 In contrast, herpangina was the most 
common diagnosis for Cox A2-infected patients.
About 20% of hospitalized EV71-infected patients had 
CNS involvement in this study, but only one patient (1%) 
progressed to cardiopulmonary failure and died. In our pre-
vious studies,12–15 the rate of CNS complications among 
EV71-infected hospitalized patients ranged from 21% to 
32%, and the rate of progression to cardiopulmonary failure 
ranged from 8% to 11%. This discrepancy in CNS compli-
cation rate may be explained by several possibilities. First, 
the indication and the bed availability for hospitalization 
may be different at different times, with the result that 
Table 3. Comparison of final diagnosis and outcome between the patients with coxsackievirus A2 and enterovirus 71a
Diagnosis EV71 (n = 97) Cox A2 (n = 183) p
Uncomplicated
 Herpangina 16 (16.5) 153 (83.6) < 0.001
 HFMD 76 (78.4) 8 (4.4) < 0.001
 Pharyngotonsilitis 1 (1.0) 13 (7.1) 0.040
 URI 2 (2.1) 4 (2.2) 1.000
 AGE 0 1 (0.5) 0.737
 Bronchopneumonia 0 2 (1.1) 0.542
 Seizure 2 (2.1) 1 (0.5) 0.260
Complicatedb 18 (18.6) 2 (1.1) 
 Aseptic meningitis 2 (2.1) 0 0.111
 Encephalitis 6 (6.2) 1 (0.5) 0.017
 Encephalomyelitis 7 (7.2) 1 (0.5) 0.006
 Pulmonary hemorrhage 1 (1.0) 0 0.335
 Myocarditis 1 (1.0) 0 0.335
 Acute paralysis 1 (1.0) 0 0.335
Outcome
 Recovery 90 (92.8) 183 (100) 0.005
 Sequelae 6 (6.2) 0 0.018
 Death 1 (1.0) 0 0.263
aData presented as n (%); b≥2 diagnoses. HFMD = Hand-foot-and-mouth disease; URI = upper respiratory infection; AGE = acute gastroenteritis.
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complication rates were different. Second, the genotype of 
the EV71 isolates circulating in Taiwan changed within the 
past decade; genotype C2 and B4 dominated the 1998 epi-
demic, then B4 prevailed in 1999–2003, C4 emerged in 
2004–2005, C5 in 2006–2007, and B5 in 2007–2008.17,18 
Further studies are required to ascertain whether the viru-
lence of the different genotypes is different. Third, the 
clinical practice may have been different at different times; 
the indication and principle for the performance of a lum-
bar puncture, for example. A lower lumbar puncture per-
formance rate may result in a lower diagnosis rate of aseptic 
meningitis. In contrast, only 1.1% of Cox A2-infected pa-
tients had CNS complications, and none progressed to 
cardiopulmonary failure.
All the patients in this study with Cox A2 infection, in-
cluding the two patients with encephalitis and encephalo-
myelitis, recovered without any sequelae. Total recovery 
was achieved in 93% of the EV71-infected patients, and 
neurologic sequelae were identified in 6.2% of EV71-
infected patients. In our previous study, the rate of neuro-
logic sequelae among EV71-infected hospitalized patients 
between 2000 and 2002 was as high as 82%.19 The better 
outcomes seen in 2008 might be due to fewer patients 
progressing to cardiopulmonary failure, as well as a well-
practiced staged-based management program.19,20
However, there are several limitations to this study as it 
is a retrospective study in nature. First, virus isolation and 
identification was not performed in every patient with pos-
sible EV71 infection who visited our hospital during the 
study period. Second, not every patient with Cox A2 or EV71 
infection was hospitalized and, subsequently, were not in-
cluded in the study. Therefore, the clinical features shown 
here cannot represent the whole picture for children with 
Cox A2 infections, but only those that were hospitalized.
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